Structural Insights on Fragment Binding Mode Conservation.

Aiming at a deep understanding of fragment binding to ligandable targets, we performed a large scale analysis of the Protein Data Bank. Binding modes of 1832 drug-like ligands and 1079 fragments to 235 proteins were compared. We observed that the binding modes of fragments and their drug-like superstructures binding to the same protein are mostly conserved, thereby providing experimental evidence for the preservation of fragment binding modes during molecular growing. Furthermore, small chemical changes in the fragment are tolerated without alteration of the fragment binding mode. The exceptions to this observation generally involve conformational variability of the molecules. Our data analysis also suggests that, provided enough fragments have been crystallized within a protein, good interaction coverage of the binding pocket is achieved. Last, we extended our study to 126 crystallization additives and discuss in which cases they provide information relevant to structure-based drug design.

[1]  Christopher W Murray,et al.  Predicting "Hot" and "Warm" Spots for Fragment Binding. , 2017, Journal of medicinal chemistry.

[2]  Malgorzata N. Drwal,et al.  Multi‐target Fragments Display Versatile Binding Modes , 2017, Molecular informatics.

[3]  Tuomo Kalliokoski,et al.  Subpocket Analysis Method for Fragment-Based Drug Discovery , 2013, J. Chem. Inf. Model..

[4]  P E Bourne,et al.  Protein structure alignment by incremental combinatorial extension (CE) of the optimal path. , 1998, Protein engineering.

[5]  Didier Rognan,et al.  Encoding Protein-Ligand Interaction Patterns in Fingerprints and Graphs , 2013, J. Chem. Inf. Model..

[6]  Christopher W Murray,et al.  Fragment-based lead discovery: leads by design. , 2005, Drug discovery today.

[7]  Akos Tarcsay,et al.  Impact of lipophilic efficiency on compound quality. , 2012, Journal of medicinal chemistry.

[8]  Matthias Rarey,et al.  Protoss: a holistic approach to predict tautomers and protonation states in protein-ligand complexes , 2014, Journal of Cheminformatics.

[9]  John Karanicolas,et al.  When Does Chemical Elaboration Induce a Ligand To Change Its Binding Mode? , 2017, Journal of medicinal chemistry.

[10]  M. Congreve,et al.  A 'rule of three' for fragment-based lead discovery? , 2003, Drug discovery today.

[11]  Károly Héberger,et al.  Why is Tanimoto index an appropriate choice for fingerprint-based similarity calculations? , 2015, Journal of Cheminformatics.

[12]  Amanda J Price,et al.  Fragment-based drug discovery and its application to challenging drug targets. , 2017, Essays in biochemistry.

[13]  Simon E. M. O'Keefe,et al.  Analysis of crystallization data in the Protein Data Bank , 2015, Acta crystallographica. Section F, Structural biology communications.

[14]  Peter M Fischer,et al.  Differential binding of inhibitors to active and inactive CDK2 provides insights for drug design. , 2006, Chemistry & biology.

[15]  I. Longden,et al.  EMBOSS: the European Molecular Biology Open Software Suite. , 2000, Trends in genetics : TIG.

[16]  Didier Rognan,et al.  Comparison and Druggability Prediction of Protein-Ligand Binding Sites from Pharmacophore-Annotated Cavity Shapes , 2012, J. Chem. Inf. Model..

[17]  Didier Rognan,et al.  sc-PDB: a 3D-database of ligandable binding sites—10 years on , 2014, Nucleic Acids Res..

[18]  S. Larson,et al.  A novel strategy for the crystallization of proteins: X-ray diffraction validation. , 2007, Acta crystallographica. Section D, Biological crystallography.

[19]  Christian Kramer,et al.  Binding Pose Flip Explained via Enthalpic and Entropic Contributions , 2017, J. Chem. Inf. Model..

[20]  R. Norton,et al.  The ways and means of fragment-based drug design. , 2016, Pharmacology & therapeutics.

[21]  P. Hajduk,et al.  A decade of fragment-based drug design: strategic advances and lessons learned , 2007, Nature Reviews Drug Discovery.

[22]  Gerhard Barnickel,et al.  Selection of fragments for kinase inhibitor design: decoration is key. , 2014, Journal of medicinal chemistry.

[23]  Gilles Marcou,et al.  Optimizing Fragment and Scaffold Docking by Use of Molecular Interaction Fingerprints , 2007, J. Chem. Inf. Model..

[24]  Cathy H. Wu,et al.  UniProt: the Universal Protein knowledgebase , 2004, Nucleic Acids Res..

[25]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[26]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[27]  Carlos Perez,et al.  Do Fragments and Crystallization Additives Bind Similarly to Drug-like Ligands? , 2017, J. Chem. Inf. Model..

[28]  Dima Kozakov,et al.  Ligand deconstruction: Why some fragment binding positions are conserved and others are not , 2015, Proceedings of the National Academy of Sciences.

[29]  Matthias Rarey,et al.  Estimating Electron Density Support for Individual Atoms and Molecular Fragments in X-ray Structures , 2017, J. Chem. Inf. Model..

[30]  J. Lawson,et al.  Fragment-Based Discovery of a Small Molecule Inhibitor of Bruton's Tyrosine Kinase. , 2015, Journal of medicinal chemistry.

[31]  M. Congreve,et al.  Fragment-based lead discovery , 2004, Nature Reviews Drug Discovery.

[32]  A. McPherson,et al.  Searching for silver bullets: an alternative strategy for crystallizing macromolecules. , 2006, Journal of structural biology.

[33]  M. P. Dillon,et al.  Structure-Guided Design of EED Binders Allosterically Inhibiting the Epigenetic Polycomb Repressive Complex 2 (PRC2) Methyltransferase. , 2017, Journal of medicinal chemistry.